INTRODUCTION
Eosinophils are bone marrow (BM)-derived cells that have key roles in homeostasis (e.g., metabolism and humoral immunity) and are implicated in the pathogenesis of numerous inflammatory processes. 1 At baseline, eosinophils reside mainly in the gastrointestinal tract, which serves as the largest eosinophil reservoir. 2 However, they are also found in substantial numbers in other organs, including the adipose tissue and uterus. 2, 3 Following type 2 helper T cell (Th2)-driven inflammatory responses or innate immune activation, such as those occurring in asthma and colitis, respectively, eosinophils are recruited into the inflamed tissue, where they modulate immune responses by releasing an array of molecules, including cytotoxic proteins, cytokines, and lipid mediators, and interact with various cell types. 2, 4 Eotaxin-1/CCL11, eotaxin-2/CCL24, and eotaxin-3/CCL26 encode for CC chemokines with eosinophil-selective chemoattractant activity. [5] [6] [7] [8] Together with their cognate receptor, CCR3 (chemokine (C-C motif) receptor 3), eotaxins play a fundamental role in eosinophil homing. 9, 10 In fact, eotaxins are critical for regulating baseline levels of eosinophils in the gastrointestinal tract and for the recruitment of eosinophils in settings of colonic inflammation and following allergen challenge in the lungs. [11] [12] [13] [14] [15] [16] [17] Despite the key roles of eotaxins in eosinophil migration, additional non-eosinophil-specific chemotactic mediators, such as macrophage inflammatory protein 1 (MIP-1a (CCL3)), regulated and normal T cell expressed and secreted (RANTES (CCL5)), and leukotrienes (LTs, especially LTC 4 and LTB 4 ), can promote eosinophil recruitment as well. [18] [19] [20] Although the activation pathways regulating eosinophil recruitment have been extensively studied, endogenous molecular pathways that are capable of restraining eosinophil accumulation have been scarcely examined. 21 The CMRF35-like molecule (CLM) family members consist of nine transmembrane glycoprotein receptors mapping to mouse chromosome 11D. Of these, CLM-1 and CLM-8 (human CD300f and CD300a, respectively) possess immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their intracellular domains and are thus able to suppress cellular activation by recruitment of phosphatases. [22] [23] [24] The in vivo roles of CLM-1 have only recently been described, owing to the generation of Clm1 À / À mice. These studies demonstrated key roles for CLM-1 in governing myeloid cell activities in experimental autoimmune encephalomyelitis and in mast cell-dependent allergic responses in mice. 25, 26 Despite these findings, the overall physiological function of CLM-1 is largely unknown and its expression and function in eosinophils has yet to be defined.
In this study, we demonstrate that CLM-1 is highly and uniquely expressed by adipose tissue and colonic eosinophils. Furthermore, we identify CLM-1 as a novel and specific negative regulator of eotaxin-induced responses in eosinophils including migration, calcium influx, actin polymerization, and intracellular signaling. To the best of our knowledge, this is the first reported evidence of a role for CLM-1 in the regulation of cellular migration. Our study highlights CLM-1 as a novel regulator of eosinophil homeostasis by specific negative regulation of cellular chemotaxis.
RESULTS

Expression of CLM-1 and CLM-8 by murine eosinophils
To define the expression of the ITIM-bearing CLM family members (e.g., CLM-1 and CLM-8) in murine eosinophils, we undertook a flow cytometric approach. Eosinophils (defined as Figure 3 ) from all the tested anatomical locations expressed CLM-1 and CLM-8 ( Figure 1a and b) . Interestingly, although peritoneal eosinophils displayed readily detectable levels of CLM-1, the expression of CLM-1 was nearly nondetectable in peritoneal macrophages (defined as CD11b þ /F480 þ cells; Figure 1b ). This expression pattern was specific for CLM-1 as both peritoneal eosinophils and peritoneal macrophages expressed comparable levels of CLM-8 ( Figure 1b) . The finding that CLM-1 was not expressed under baseline conditions by peritoneal macrophages was further confirmed by staining Clm1 À / À peritoneal macrophages with anti-CLM-1 or isotype-matched control antibodies, which revealed no CLM-1 þ macrophages (Figure 1c) . Notably, anti-CLM-1-stained Clm1
À / À cells displayed identical fluorescent intensity levels as the isotype control-stained Clm1 À / À cells.
Unique expression of CLM-1 by adipose tissue and colonic eosinophils
The unique expression of CLM-1 in peritoneal eosinophils in comparison with macrophages raised the possibility that tissue eosinophils would specifically express CLM-1 as well. Indeed, colonic and adipose tissue eosinophils (as defined by CD45 þ /Siglec-F þ /CD11b þ cells) consistently expressed CLM-1 and CLM-8 (Figure 2a and b) . Strikingly, however, CLM-1 expression was completely absent in colonic macrophages (defined by CD45
À cells), very low in dendritic cells (DCs, as defined by Figure 2a and d) and nearly nondetectable in adipose tissue macrophages (defined as CD45 þ /CD11b high /F4/80 þ cells), respectively (Figure 2b and d) . Consistently, analysis of CLM-1 mRNA expression in sorted colonic macrophages and eosinophils revealed that eosinophils express markedly higher levels of CLM-1 mRNA levels in comparison with macrophages ( Figure 2c) . Interestingly, and in contrast to CLM-1 expression in adipose tissue and colonic macrophages, BM, splenic, and alveolar macrophages displayed readily detectable levels of CLM-1 (see Supplementary Figure S1 online).
Analysis of CLM-1 levels in peripheral blood neutrophils and monocytes (Ly6G þ /CD11b þ and Ly6C high /CD11b þ cells, respectively) revealed that circulating neutrophils and monocytes express similar levels of CLM-1 as peripheral blood eosinophils (Figure 2e ; also see Figure 1a ). Collectively, these results demonstrate that under homeostatic conditions ,the highest CLM-1-expressing cells in the colon and adipose tissue are eosinophils, at least in comparison with macrophages and DCs.
CLM-1 regulates baseline tissue eosinophil levels
The unique expression for CLM-1 in eosinophils prompted us to assess eosinophil levels in Clm1 À / À mice. BM and peripheral blood eosinophil levels were comparable between wild-type (WT), Clm1 À / À , and Clm8 À / À mice ( Figure 3a, b and g ). In contrast, Clm1 À / À mice displayed a two-to three-fold increase in peritoneal, gastrointestinal, and adipose tissue eosinophil levels as compared with WT and Clm8 À / À mice ( Figure 3c-e and g ). À / À mice displayed decreased baseline eotaxin-1 and eotaxin-2 levels in the colon and had no difference in eotaxin-1 and/or eotaxin-2 expression in the peritoneal cavity and/or adipose tissue. Moreover, Clm1 À / À eosinophils expressed similar CCR3 surface levels when compared with WT eosinophils (Supplementary Figure S2 online).
CLM-1 negatively regulates eotaxin-induced eosinophil responses
As BM and blood eosinophil levels were similar in WT and Clm1 À / À mice ( Figure 3a and b), yet Clm1 À / À mice displayed elevated tissue eosinophilia (Figure 3c -e), we hypothesized that CLM-1 negatively regulates eosinophil trafficking. To examine this hypothesis, in vitro chemotaxis assays were performed. Indeed, following stimulation with eotaxin-1 or eotaxin-2, Clm1 À / À low-density BM-derived eosinophils displayed significantly increased chemotaxis in a dose-dependent manner (Figure 4a and b) . For example, addition of 100 ng ml À 1 eotaxin-1 or eotaxin-2 to the lower chambers of the trans-well system induced a 10-fold increase in WT eosinophil chemotaxis, whereas Clm1 À / À eosinophils displayed a 20-to 25-fold increase (Figure 4a, b) . Consistently, eotaxin-1-induced calcium influx was increased in Clm1 To further establish the role of CLM-1 in eotaxin-1-induced eosinophil chemotaxis, a direct in vivo approach was used in which eotaxin-1 was directly injected into the peritoneal cavity and eosinophil recruitment was assessed. Consistent with previous publications, 27 administration of eotaxin alone was not sufficient to induce significant eosinophil accumulation in the peritoneal cavity of WT mice (Figure 4g-i) . In contrast, eotaxin-1 administration to Clm1 À / À mice induced a significant influx of eosinophils to the peritoneal cavity, with their levels reaching 17-24% of all peritoneal leukocytes (Figure 4g -i).
CLM-1 does not regulate MIP-1a-and LTB 4 -induced eosinophil or neutrophil chemotaxis
Next, we determined whether the inhibitory function of CLM-1 is specific to CCR3 ligands, or if it can suppress additional chemotactic signals in eosinophils. In contrast to our findings with eotaxin-1 and eotaxin-2 ( Figure 4a and b) , the chemotactic responses of Clm1 À / À and WT eosinophils to MIP-1a and LTB 4 were similar (Figure 5a and b) . Supporting these results, ex vivo neutrophil chemotaxis assays using naive splenocyte cell suspension demonstrated that Clm1 
neutrophils (as determined by CD45
þ /CD11b þ /Gr-1 þ / SSC int ) displayed essentially the same chemotactic activity as WT neutrophils in response to LTB 4 and MIP-1a stimulation (Figure 5c-e) . Thus, CLM-1 is a novel regulator of eotaxininduced eosinophil chemotaxis.
CLM-1 binds apoptotic eosinophils and regulates eosinophil chemotaxis via receptor/ligand interactions
The finding that Clm1 À / À eosinophils displayed increased responses to eotaxin-induced stimulation in vitro suggested that CLM-1/ligand interactions are required to suppress À / À mice and subjected to chemotaxis assays using (a, d) LTB 4 and (b, e) MIP-1a at the indicated concentrations. (c) The gating strategy for detection of splenic neutrophils is depicted; n ¼ 3. FSC, forward scatter; Neut, neutrophil; NS, nonsignificant; SSC, side scatter.
eotaxin-induced eosinophil chemotaxis. CLM-1 was recently demonstrated to bind phosphatidylserine, which is expressed on the surface of apoptotic cells. 28 Thus, we assessed the possibility that CLM-1 binds apoptotic eosinophils. To this end, BM-derived eosinophils were stained with Annexin-V together with IgG1 CLM-1-Fc or control fusion proteins. CLM-1 was capable of binding apoptotic eosinophils (as determined by annexin-V þ cells) but not viable cells (Figure 6a ). To further explore the role of CLM-1/ligand interactions in the regulation of eosinophil chemotaxis, WT eosinophils were incubated in the presence of IgG1 CLM-1-Fc fusion protein, which competes with cellular-expressed CLM-1 for ligand binding, resulting in decreased CLM-1 signaling. 26 Thereafter, the cells were stimulated with eotaxin and assessed for their chemotactic activity. Notably, CLM-1-Fc fusion protein-treated WT eosinophils displayed significantly increased chemotaxis in response to eotaxin in comparison with that of control Fcfusion protein-treated cells (Figure 6b) . Furthermore, addition of increasing concentrations of phosphatidylserine to WT eosinophil chemotaxis assays revealed a significant reduction in the ability of eosinophils to respond to eotaxin (Figure 6c) .
Collectively, these data demonstrate a key role for CLM-1/ ligand interactions in the regulation of eosinophil chemotaxis CLM-1/ligand interactions regulate eosinophil accumulation during allergic airway inflammation Next, we were interested to determine whether eosinophil migration will be regulated by CLM-1 in the context of eosinophilic airway disease, which induces an eotaxin-dependent chemotactic gradient accountable for eosinophil accumulation. 29 As CLM-1 is expressed by various cells including DCs and B cells, 24 which are required for the sensitization phase of allergic airway inflammation, we chose a model that would assess the function of CLM-1 in the effector phase of allergic airway disease without affecting sensitization (Figure 6d) . To this end, WT mice were sensitized twice with ovalbumin (OVA)/Alum (on days 0 and 14). Thereafter, 1 h before the subsequent OVA challenges, the mice were intranasally administered a CLM-1-Fc (or control-Fc) fusion protein (Figure 6d) .
Assessment of eosinophil accumulation in the lungs following the last OVA challenge revealed a specific and significant increase in eosinophil accumulation in the CLM-1-Fc fusion protein-treated mice in comparison with control-Fc fusion-treated mice (Figure 6e) . Increased eosinophil accumulation was not due to increased eosinophil survival factors (e.g., interleukin 5 (IL-5)) or chemokines (e.g., eotaxins) as the levels of these mediators in the bronchoalveolar lavage fluid were similar in the mice treated with OVA, OVA þ Control-Fc, and OVA þ CLM-1-Fc fusion proteins (Figure 6f, g ).
Human peripheral blood eosinophils express CD300f that is upregulated in active allergic rhinitis patients Given the expression of CLM-1 by murine eosinophils, we next aimed to identify whether human eosinophils express CD300f, the human ortholog of CLM-1. 24 Although CD300f is known to be expressed and functional in various human myeloid cells, its expression and function in human eosinophils is unknown. To this end, eosinophils were purified from the peripheral blood of healthy volunteers and CD300f expression was examined by PCR ( Figure 7a) . Human eosinophils expressed substantial levels of CD300f, similar to those expressed by the monocytic cell line U937 (Figure 7a) . Flow cytometric analysis confirmed that eosinophils express readily detectable levels of CD300f on their surface (Figure 7b) .
Previous studies have shown that diverse stimuli can induce a rapid upregulation of inhibitory receptors that then act as a negative feedback loop to restrain cellular activation. 30 Flow cytometric analysis of CD300f expression by peripheral blood eosinophils in allergic rhinitis patients (as defined by CD45
À /SSC high ) revealed significantly elevated levels of CD300f surface expression in comparison with healthy individuals (Figure 7c and d) .
DISCUSSION
The migration of inflammatory cells from the blood stream into interstitial spaces is a cornerstone of the inflammatory process and critically regulated by chemokines. Specifically, eotaxins, via their respective CCR3 receptor, play a fundamental role in governing eosinophil migration in health and disease. 1, 2, 14, 31 Therefore, endogenous molecular pathways that can counterregulate the migratory responses of eosinophils may have considerable implications for disease therapy as specific inhibitory receptor agonists could be designed to curtail eosinophil accumulation. [32] [33] [34] In an attempt to define novel negative regulators of eosinophil functions, we examined the expression and function of CLM-1 in eosinophils. We demonstrated that: (i) CLM-1 is highly and almost exclusively expressed by colonic and adipose tissue eosinophils in comparison with other resident myeloid cells; (ii) the selective expression of CLM-1 in eosinophils corresponds with increased baseline eosinophilia in Clm1 À / À but not Clm8 À / À mice; (iii) CLM-1 is a specific regulator of eotaxin-induced eosinophil responses in vitro (e.g., chemotaxis, calcium influx, actin polymerization, and signaling) and in vivo; (iv) CLM-1/ ligand interactions govern eosinophil migration in vitro and in settings of allergic airway disease; and finally (v) human eosinophils express CD300f that is upregulated in peripheral blood eosinophils obtained from allergic rhinitis patients.
Collectively, our results demonstrate a novel physiological role for CLM-1 in eosinophil homeostasis by governing eotaxininduced eosinophil responses. These data substantially enhance our understanding of the molecular mechanisms that govern eosinophil accumulation in the tissue in health and disease. Although eosinophils have been a therapeutic target for many years, there is a surprising paucity of studies regarding the expression and function of ITIM-bearing receptors that are expressed by these cells, especially in vivo. The CLM family of receptors consists of nine members; of these, CLM-1 and 8 (human CD300f and CD300a, respectively) are considered inhibitory as they contain various ITIMs in their intracellular domain and can recruit cellular phosphatases consequently suppressing cellular activation. 24 Indeed, our findings highlight an exclusive role for CLM-1 in the negative regulation of eosinophils. Recent studies (including our own) emphasize the importance of ITIM-bearing receptors in eosinophil homeostasis via regulation of various signaling pathways. For example, mice that lack most of the cytoplasmic domain of the ITIM-bearing receptor, signal regulatory protein (SIRP)-1a (SIRPa Cyto À / À mice), or CD47, the ligand for SIRP-1a, display elevated degranulation of intestinal eosinophils. 35 Interestingly, this degranulation was associated with fewer lamina propria eosinophils, likely due to regulation of IL-5-induced eosinophil survival by SIRP-1a. 35 Furthermore, gastrointestinal eosinophils express the pan-B-cell marker CD22, and although the mechanism for this is unclear, Cd22 À / À mice display elevated gastrointestinal eosinophilia. In addition, we have recently shown that paired immunoglobulin-like receptor B (PIR-B) has a complex role in the regulation of eosinophil migration. Although PIR-B suppressed eosinophil migration in response to eotaxins, it positively regulated LTB 4 -induced migratory responses. The ability of PIR-B to suppress cellular migration was not confined to eosinophils as it could negatively regulate DCs and neutrophil chemotaxis as well. 36, 37 Of note, PIR-B was capable of suppressing MIP-1a-induced neutrophil chemotaxis. Thus, to the best of our knowledge, this is the first report demonstrating an endogenous receptor-mediated pathway (i.e., CLM-1) that can specifically suppress eotaxin-induced responses in eosinophils.
Mechanistically, we have shown that CLM-1 negatively regulates eotaxin-induced calcium influx, actin polymerization, and phosphorylation of ERK but not p38. It is important to note that although activation of eosinophils with CCR3 ligands has been shown to induce calcium influx and cytoskeleton rearrangements, suppression of eosinophil transmigration was not always associated with alterations in calcium influx. Most relevant, we have recently shown that induction of an inhibitory signaling cascade in human eosinophils by CD300a using artificial antibody crosslinking resulted in suppression of eosinophil chemotaxis in vitro. 38 Interestingly and despite decreased chemotaxis in CD300a-activated cells, eotaxininduced calcium influx was not altered. 38 Similarly, Fulkerson et al. 39 have shown that inhibition of eosinophil transmigration by Mig does not require the inhibition of calcium influx. It is likely that the ability of ITIM-bearing receptors such as CD300a or CLM-1 to suppress calcium influx is dependent on their interaction with downstream adaptor molecules that are recruited to the receptor following cellular activation. Alternatively, it has recently been shown that all CD300 family members interact with each other, even with themselves and are capable of forming both homo-and heterodimers. Thus, the inhibitory signaling capacity of each CD300/CLM family member may be dependent on the expression of additional CD300/CLM-molecules. 40 Defining the full expression and functional spectrum of CD300/CLM-1 family members in eosinophils will likely shed more light into these interactions and their relevance in eosinophil biology.
Importantly, the increased responsiveness of Clm1 À / À eosinophils to eotaxin was not due to elevated levels of CCR3 on the surface of Clm1 À / À eosinophils or to increased tissue eotaxin levels. In fact, the expression of eotaxin was markedly reduced in the colon of Clm1 À / À mice. This observation may be partially explained by the fact that Clm1 À / À eosinophils have increased eotaxin consumption. Alternatively, it is possible that albeit low expression levels, CLM-1 regulates baseline eotaxin production by resident colonic myeloid cells such as macrophages and/or DCs. 41 The finding that the expression of CLM-1 is associated predominantly with eosinophils and not other myeloid cells is of quite interest, especially as, to date, the common knowledge was that CLM-1 or CD300f is mainly expressed by monocytes, DCs, and macrophages. 23, 28, [42] [43] [44] The elevated baseline eosinophilia in Clm1 À / À mice in combination with the relatively eosinophil-associated expression pattern suggests that CLM-1 is constitutively active in eosinophils and that its ligand is readily accessible to these cells. Recent studies have indicated that CLM-1 (and additional CD300/CLM family members) can bind various ligands, including extracellular ceramide, phosphatidylcholine, sphingosyl, phosphatidylserine, and high-density and low-density lipoproteins. 25, 28, 45, 46 Directly related, we now show that CLM-1 binds apoptotic eosinophils and that phosphatidylserine is capable of suppressing eosinophil chemotaxis (at least in vitro), likely by interacting with CLM-1. These findings suggest that recruitment of eosinophils to sites of tissue damage and cell death 47 is actively regulated by intrinsic negative feedback mechanisms such as CLM-1.
Furthermore, upon binding to ceramide, CLM-1 was capable of suppressing mast cell-induced activation, resulting in exacerbated mast cell-dependent allergic responses in Clm1 À / À mice such as anaphylaxis, dermatitis, and airway inflammation. 25 Certainly, intranasally OVA-challenged Clm1 À / À mice displayed increased airway eosinophilia that was associated with increased Th2 cytokine production. 25 Although increased eosinophilia in the latter study was attributed mainly to increased activation of mast cells, it is likely that increased eosinophil accumulation is regulated at least in part by direct negative signaling of CLM-1 in response to eotaxins. In support of this view, we demonstrate that blockade of CLM-1/ligand interactions in the effector stage of OVA-induced allergic inflammation induced a specific increase in eosinophil accumulation in the lungs. Although our in vivo studies cannot exclude the possible contribution of CLM-1 expression by additional myeloid cells, the finding that only eosinophil accumulation (but not neutrophil infiltration) was increased is consistent with our in vitro data that demonstrated a specific effect for CLM-1 in eotaxin-induced eosinophil (but not neutrophil) chemotaxis. Although our studies focused on eosinophils, it is possible that CLM-1 may regulate eotaxininduced responses in additional CCR3
þ and eotaxin-responsive cells (e.g., basophils).
As many of the in vitro studies described herein were conducted using eosinophils that were obtained from longterm culture in the presence of IL-5, we cannot exclude a possible interaction between IL-5 and CLM-1 that might affect eosinophil priming and subsequent migration. Nevertheless, this is unlikely as we observed increased eotaxin-induced chemotactic responses in vivo (in the absence of exogenous IL-5). Furthermore, inflammatory conditions promoting tissue eosinophilia are associated with increased IL-5. 48 Thus, our results may actually reflect how CLM-1 regulates eosinophils under disease conditions. Finally, we demonstrate for the first time that CD300f is expressed by human eosinophils and that its expression is elevated in cells obtained from allergic rhinitis patients. This observation is important as it indicates that a factor in the inflammatory environment regulates the expression of CLM-1 that in turn can negatively regulate cellular responses in allergic settings, thereby providing a new inhibitory feedback mechanism in eosinophils.
In summary, our results establish a key role for CLM-1 in eosinophil homeostasis in health and disease. These data provide fundamental insights into negative regulation of eosinophils by inhibitory receptors (in general) and illustrate a model in which eosinophil tissue recruitment is constantly restrained by CLM-1 serving as a novel molecule restricting eotaxin-induced eosinophil homing signals.
METHODS
Mice. The generation of Clm1
À / À mice has been previously described. 26 Clm8 À / À mice (B6N.129S5-Cd300atm1Lex/Mmcd, ID 032182-UCD) were obtained from the Mutant Mouse Regional Resource Center (MMRC, University of California, Davis, CA; originally donated by Genentech) and backcrossed to C57BL/6 mice for 10 generations. WT C57BL/6 mice were originally obtained from Harlan Laboratories (Rehovot, Israel) and grown in-house. In all experiments, age-, weight-, and sex-matched mice were used and housed under specific pathogen-free conditions according to protocols approved by the Tel-Aviv University Institutional Animal Care Unit.
Mouse and human eosinophils. Mouse low-density BM-derived eosinophils were generated as previously described. 49 Eosinophil purity was assessed by cytological analysis (Diff-Quick, Emmonya Biotech Ltd, Chelopech, Bulgaria) and CCR3/Sialic acid-binding immunoglobulin-like lectin-F (Siglec-F) positivity (flow cytometry) and were consistently 490%. For analysis of human eosinophils, blood samples were drawn from subjects treated at Meir Medical Center, Kfar Saba, Israel. Allergic patients were defined as subjects with a history of rhinitis and positive skin-prick test for at least one aeroallergen. The Institutional Review Board approved the study and all subjects signed an informed consent form. Before recruitment of the first subject, the protocol was registered at ClinicalTrials.gov (ID NCT01489293).
Generation of single-cell suspensions. Single-cell suspensions from the peritoneum, blood, BM, spleen, intestine, and adipose tissue (using the ''walking out'' technique) of WT, Clm1 À / À , and Clm8
À / À mice were obtained as described previously. . For human peripheral blood stainings, the following anti-human antibodies were used: anti-CD16-PE-Cy7, anti-CCR3-APC-Cy7 (all from Biolegend), anti-Siglec-8-PE (BD Biosciences, San Jose, CA), anti-CLM-1-Alexa Fluor 647, rat IgG1, and k-Alexa Fluor 647 (all from eBioscience). Flow cytometry was performed using a 3-laser 10-color Gallios flow cytometer (Beckman Coulter, Brea, CA) and data were analyzed using Kaluza (Beckman Coulter) or FlowJo v10.3 (TreeStar, Ashland, OR) analysis software. All staining procedures were conducted following blocking with either 10% fetal calf serum or using an Fc-blocking reagent (eBioscience). Median fluorescent intensity (MFI) was obtained and DMFI calculated as previously described.
37
Phosphoflow. Eotaxin-induced ERK-1/2 and p38 phosphorylation were assessed as previously described. 38 Calcium influx. Eotaxin-induced calcium influx was assessed by flow cytometry using Fluo-4AM (4 mM, Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
Chemotaxis assay. In vitro chemotaxis assays were conducted as previously described. 37 In several experiments, chemotaxis assays were performed in the presence of phosphatidylserine (Sigma, Rehovot, Israel). Alternatively, CLM-1/ligand interactions were blocked using an IgG1 CLM-1-Fc fusion protein (5 mg ml À 1 ) or appropriate IgG1 control Fc fusion protein. 26 In other experiments, single-cell suspensions from spleens were obtained and stained with anti-CD45, anti-Gr-1, and anti-CD11b for identification of neutrophils. Thereafter, the cells were washed and chemotaxis assays were performed. 37 In vivo chemotaxis assay. Eotaxin-1 (1 mg per 200 ml saline) or saline were injected intraperitoneally into WT and Clm1 À / À mice. After 3 h, the mice were killed, their peritoneal cavities washed, and cells were collected and counted. The percentage of eosinophils was determined by flow cytometry using anti-CD45, anti-Siglec-F, and anti-CD11b as described above.
Allergic eosinophilic airway inflammation. Allergic eosinophilic airway inflammation was induced in WT mice using OVA/Alum as described previously. 51 CLM-1/ligand interactions were blocked by intranasal administration of CLM-1-Fc fusion protein or control IgG1 fusion protein (20 mg /ml À 1 , 1 h before allergen challenge). Thereafter, bronchoalveolar lavage fluid was performed and accumulation of lung eosinophils assessed by cytological staining (Diff-Quick).
Enzyme-linked immunosorbent assay. Chemokines and cytokines were measured by enzyme-linked immunosorbent assay as described elsewhere. 51 The lower detection limits for CCL11, CCL24, and IL-5 were 7.8, 15.6, and 15.6 pg ml , respectively (Duo-Set, R&D Systems). Peritoneal cavity chemokine levels were assessed after the peritoneal cavity was washed and the peritoneal fluid concentrated using centrifugal concentrators (3,000 molecular weight cutoff; Vivaspin, Gottingen, Germany).
